CN114309636B - Chiral gold nano antibacterial material and preparation method thereof - Google Patents
Chiral gold nano antibacterial material and preparation method thereof Download PDFInfo
- Publication number
- CN114309636B CN114309636B CN202111633546.7A CN202111633546A CN114309636B CN 114309636 B CN114309636 B CN 114309636B CN 202111633546 A CN202111633546 A CN 202111633546A CN 114309636 B CN114309636 B CN 114309636B
- Authority
- CN
- China
- Prior art keywords
- solution
- chiral
- gold nano
- gold
- antibacterial material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 239000010931 gold Substances 0.000 title claims abstract description 85
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 83
- 239000000463 material Substances 0.000 title claims abstract description 30
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000000243 solution Substances 0.000 claims description 144
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 44
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 27
- 229960005070 ascorbic acid Drugs 0.000 claims description 22
- 235000010323 ascorbic acid Nutrition 0.000 claims description 22
- 239000011668 ascorbic acid Substances 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 20
- 108010016626 Dipeptides Proteins 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 239000002086 nanomaterial Substances 0.000 abstract description 10
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 241000251511 Holothuroidea Species 0.000 abstract description 2
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 8
- 241000191963 Staphylococcus epidermidis Species 0.000 description 7
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002082 metal nanoparticle Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100027881 Tumor protein 63 Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention belongs to the technical field of material chemistry, and particularly discloses a chiral gold nano antibacterial material and a preparation method thereof. According to the invention, gold nano bipyramids are used as seeds, and chiral gold nano materials with different sea cucumber shapes are obtained through the added chiral ligand. The transmission electron microscope proves that the prepared nanostructure has good dispersibility and uniformity, the synthesized sea cucumber-like chiral gold nanomaterial has a stable structure, and the prepared sample is unchanged after being placed at normal temperature for a long time. Meanwhile, the product obtained by the invention has excellent chiral property and good photo-thermal effect, and has remarkable sterilization effect.
Description
Technical Field
The invention belongs to the field of material chemistry, and particularly relates to a chiral gold nano antibacterial material and a preparation method thereof.
Background
Noble metal nanomaterials (gold, silver) have attracted a lot of research due to their high specific surface, controllable morphology and many surface binding sites. In recent years, the research on the controllable preparation of the size, shape and composition of the metal nano-particles becomes a hot spot, and simultaneously, more routes and wide application including photoelectrocatalysis, nano-biosensors, tumor biological imaging and medical diagnosis and treatment are provided for the research on the surface plasma performance of the metal nano-particles. The wet chemical synthesis method is widely applied to the preparation of noble metal nano particles due to low cost and large scale.
In addition to gold nanorods, gold nanobipyramids are another elongated gold nanocrystal with an adjustable longitudinal plasmon resonance wavelength (LSPR). The gold nanometer bipyramid consists of two pentagonal prisms with bottoms connected together, and has two sharp peaks, and the gold nanometer bipyramid is more stable than the gold rod. Compared with the gold nanorod, the gold nano bipyramid has sharper top end and narrower morphology and size distribution, so that the extinction section and the local electric field enhancement of the gold nano bipyramid are much stronger than those of the gold nanorod.
Sepsis (sepsis) is a life threatening disease caused by a deregulation of the host's immune response to infection, resulting in tissue damage and organ dysfunction, with a high mortality rate. Its etiology involves mainly bacterial (gram negative and gram positive), viral and fungal pathogens. Staphylococcus epidermidis is the most common organism in foreign implant-related infections, such as prosthetic joints, central venous catheters, cerebrospinal fluid shunts, endocardial devices, prosthetic heart valves, and vascular grafts. Furthermore, drug resistant bacteria have become a serious global health problem due to the widespread overuse of antibiotics and the formation of biofilms. The nanomaterial has adjustable physicochemical properties (such as shape, particle size, surface charge, composition and the like) and characteristics such as easiness in surface modification and the like, and thus has great potential in treating diseases such as septicemia, implanted bacterial infection and the like.
Disclosure of Invention
The invention provides a chiral gold nanomaterial with adjustable plasma formants and sea cucumber-like morphology for resisting bacterial and biomembrane infection, and provides a promising nanometer tool for resisting deadly bacterial infection, regulating systemic inflammatory response, preventing multiple organ failure and the like and improving sepsis treatment effect. The preparation method of the chiral gold nano antibacterial material comprises the following specific steps:
(1) To HAuCl 4 Adding citric acid solution into the solution, uniformly mixing, adding a reducing agent, and reacting to obtain gold seed solution;
(2) Performing heat treatment on the gold seed solution;
(3) Adding the gold seed solution after heat treatment into a water growth solution to obtain a gold nano bipyramid solution, wherein the water growth solution is a mixed solution of CTAB, silver nitrate, hydrochloric acid and ascorbic acid;
(4) Adding chiral dipeptide aqueous solution and the gold nanometer bipyramid solution into growth solution, and reacting to prepareThe chiral gold nano antibacterial material is obtained, and the growth solution is prepared from CTAB and HAuCl 4 Is prepared by adding ascorbic acid solution.
Preferably, in the step (1), the reducing agent is NaBH 4 And/or KBH 4 。
Preferably, the concentration of the gold seed solution is 0.2-0.3mM.
Preferably, in the step (2), the heat treatment is performed under the condition of stirring at 70-90 ℃ for 60-120min.
Preferably, in the step (3), the molar ratio of CTAB, silver nitrate, hydrochloric acid and Ascorbic Acid (AA) in the water growth solution is 1000:1-5:1-5:10-20.
Specifically, the water growth solution can be obtained by mixing 10mL of CTAB solution (100 mM), 0.1-0.5mL of silver nitrate aqueous solution (10 mM), 1-5mL of hydrochloric acid (1M), and 0.1-0.2mL of AA solution (100 mM).
Preferably, the chiral dipeptide is a dipeptide obtained by condensing cysteine and phenylalanine, in particular L-CF, D-CF or DL-CF.
Preferably, in the step (4), the Au in the gold nano bipyramid solution 3+ 、CTAB、HAuCl 4 The molar ratio of the ascorbic acid to the chiral dipeptide is 1-25:5-100:1.5-4.5:7.5-12.5:0.04-0.12.CTAB solution with concentration of 5-100mM, HAuCl 4 The concentration of the aqueous solution is 5-15mM, the concentration of the ascorbic acid solution is 75-125mM, and the concentration of the L/D-CF solution is 0.5-1.5mM; CTAB solution, HAuCl 4 The volume ratio of the aqueous solution, the ascorbic acid solution and the L/D-CF aqueous solution is 1:0.3:0.1:0.08.
preferably, in the step (4), the reaction condition is 25-35 ℃ for 1.5-2.5h.
The invention provides a chiral gold nano antibacterial material prepared by the preparation method.
Further, the grain diameter range of the chiral gold nano antibacterial material is 80-150nm.
Compared with the prior art, the technical scheme of the invention has the following advantages:
the product has good photo-thermal effect and chiral property, and has targeting property on bacteria. The composition has good performance in killing planktonic bacteria and removing biological membranes, and solves the problem of potential thermal damage to normal tissues caused by the fact that bacteria are not targeted by the traditional treatment means. The invention constructs a chiral dipeptide functionalized gold nano bipyramid material which is used for enhancing PTT based on chemical and physical interaction with bacteria and has remarkable sterilization effect.
Drawings
FIG. 1 is a flow chart of a preparation method of the chiral gold nano-antibacterial material.
FIG. 2 is a transmission electron microscope photograph and SEM photograph of the chiral gold nano-antibacterial material prepared by the present invention.
FIG. 3 is a Circular Dichroism (CD) chart of the chiral gold nano-antibacterial material prepared by the present invention.
FIG. 4 is an ultraviolet diagram of the chiral gold nano-antibacterial material prepared by the invention.
FIG. 5 is a graph showing the temperature change of a staphylococcus epidermidis solution after treatment by various methods.
FIG. 6 is a graph depicting bacterial viability of Staphylococcus epidermidis treated by various methods.
FIG. 7 is a graph of bacterial colonies of Staphylococcus epidermidis after treatment by various methods.
FIG. 8 is an image of live/dead fluorescence of bacteria treated by different methods (live/dead bacteria stained with green/red fluorescence, respectively).
FIG. 9 is an SEM image of Staphylococcus epidermidis after treatment by various methods.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and specific examples, which are not intended to be limiting, so that those skilled in the art will better understand the invention and practice it.
Example 1
Take 0.025mL 100mM HAuCl 4 Adding 3mL of water into the solution, and mixing to obtain a solution A; to solution A, 5mL100mM CTAC (cetyltrimethylammonium chloride) and 1mL 50mM citric acid solution were added, and 0.625mL100mM NaBH was added immediately after stirring 4 Stirring the solution for 3min to obtain a solutionAnd (3) a liquid B. Solution B was stirred in an oil bath at 80℃for 90min to give a 0.25mM gold seed solution, which was concentrated to give a 100mM gold seed solution C. Simultaneously, a water growth solution containing 10mL 100mM cetyltrimethylammonium bromide aqueous solution (CTAB), 0.2mL 10mM silver nitrate, 2mL 1M hydrochloric acid and 0.15mL 100mM ascorbic acid was prepared, 100. Mu.L of gold seed solution C was added thereto, the mixture was stored at 30℃for 2 hours, and the precipitate was taken out by centrifugation and dissolved in 1mL 0.1mol/L CTAB solution to obtain gold nanoparticle bipyramid solution D.
To 20mL of the aqueous solution were added 1mL of 100mM CTAB solution and 0.3mL of 10mM HAuCl 4 Stirring the solution, adding 0.1mL of 100mM ascorbic acid solution to obtain a growth solution A, adding 0.08mL of 1mM chiral dipeptide (DL-CF) solution into the growth solution A, adding 0.4mL of gold nano bipyramid solution D, and standing at 30 ℃ for 2h to obtain chiral gold nano antibacterial material DL-GBPs with sea cucumber-like morphology.
Example 2
Take 0.025mL 100mM HAuCl 4 Adding 3mL of water into the solution, and mixing to obtain a solution A; to solution A, 5mL of 100mM CTAC and 1mL of 50mM citric acid solution were added, and immediately after stirring, 0.625mL of 100mM NaBH was added 4 The solution was stirred for 3min to give solution B. Solution B was stirred in an oil bath at 80℃for 90min to give a 0.25mM gold seed solution, which was concentrated to give a 100mM gold seed solution C. Simultaneously preparing a water growth solution containing 10mL 100mM CTAB, 0.2mL 10mM silver nitrate, 2mL 1M hydrochloric acid and 0.15mL 100mM ascorbic acid, adding a gold seed solution C into the water growth solution, standing and preserving for 2h at 30 ℃, centrifuging, taking a precipitate thereof, and dissolving the precipitate in 1mL 0.1mol/L CTAB solution to obtain a gold nano bipyramid solution D.
To 20mL of the aqueous solution were added 1mL of 95mM CTAB solution and 0.3mL of 12mM HAuCl 4 Stirring the solution, adding 0.1mL 110mM ascorbic acid solution to obtain a growth solution A, adding 0.08mL 1.0mM chiral dipeptide (L-CF) solution into the growth solution A, adding 0.4mL gold nano bipyramid solution D, and standing at 30 ℃ for 2h to obtain the chiral gold nano antibacterial material L-GBPs with sea cucumber-like morphology.
Example 3
Take 0.025mL 100mM HAuCl 4 Adding 3mL of water into the solution, and mixing to obtain a solution A; to the solutionAdd 5mL of 100mM CTAC and 1mL of 50mM citric acid solution to solution A, stir well and immediately add 0.625mL of 100mM NaBH 4 The solution was stirred for 3min to give solution B. Solution B was stirred in an oil bath at 80℃for 90min to give a 0.25mM gold seed solution, which was concentrated to give a 100mM gold seed solution C. Simultaneously preparing a water growth solution containing 10mL 100mM CTAB, 0.2mL 10mM silver nitrate, 2mL 1M hydrochloric acid and 0.15mL 100mM ascorbic acid, adding a gold seed solution C into the water growth solution, standing and preserving for 2h at 30 ℃, centrifuging, taking a precipitate thereof, and dissolving the precipitate in 1mL 0.1mol/L CTAB solution to obtain a gold nano bipyramid solution D.
To 20mL of the aqueous solution were added 1mL of 100mM CTAB solution and 0.3mL of 10mM HAuCl 4 Stirring the solution, adding 0.1mL of 100mM ascorbic acid solution to obtain a growth solution A, adding 0.08mL of 1.0mM chiral dipeptide (D-CF) solution into the growth solution A, adding 0.4mL of gold nano bipyramid solution D, and standing at 30 ℃ for 2 hours to obtain the chiral gold nano material D-GBPs with sea cucumber-like morphology.
Example 4
Take 0.025mL 100mM HAuCl 4 Adding 4mL of water into the solution, and mixing to obtain a solution A; add 5mL of 100mM CTAC and 1mL of 50mM citric acid solution to solution A, stir well and immediately add 0.625mL100mM NaBH 4 The solution was stirred for 4min to give solution B. Solution B was stirred in an oil bath at 70℃for 120min to give a 0.25mM gold seed solution, which was concentrated to give a 100mM gold seed solution C. Simultaneously preparing a water growth solution containing 10mL 100mM CTAB, 0.2mL 10mM silver nitrate, 1mL 1M hydrochloric acid and 0.15mL 100mM ascorbic acid, adding a gold seed solution C into the water growth solution, standing and preserving for 2h at 30 ℃ and centrifuging at 600 rpm for 10min, and dissolving the precipitate in 1mL 0.1mol/L CTAB solution to obtain a gold nano bipyramid solution D.
To 20mL of the aqueous solution were added 1mL of 100mM CTAB solution and 0.3mL of 10mM HAuCl 4 Stirring the solution, adding 0.1mL of 100mM ascorbic acid solution to obtain a growth solution A, adding 0.08mL of 1.0mM chiral dipeptide (D-CF) solution into the growth solution A, adding 0.4mL of gold nano bipyramid solution D, and standing at 30 ℃ for 2 hours to obtain the chiral gold nano material D-GBPs with sea cucumber-like morphology.
Example 5
Take 0.025mL 100mM HAuCl 4 Adding 4mL of water into the solution, and mixing to obtain a solution A; to solution A, 5mL of 100mM CTAC and 1mL of 50mM citric acid solution were added, and immediately after stirring 0.625mL100mM NaBH 4 The solution was stirred for 4min to give solution B. Solution B was stirred in an oil bath at 90℃for 60min to give a 0.25mM gold seed solution, which was concentrated to give a 100mM gold seed solution C. Simultaneously preparing a water growth solution containing 10mL 100mM CTAB, 0.2mL 10mM silver nitrate, 1mL 1M hydrochloric acid and 0.15mL 100mM ascorbic acid, adding a gold seed solution C into the water growth solution, standing and preserving for 2h at 30 ℃, centrifuging, taking a precipitate thereof, and dissolving the precipitate in 1mL 0.1mol/L CTAB solution to obtain a gold nano bipyramid solution D.
To 20mL of the aqueous solution were added 1mL of 100mM CTAB solution and 0.3mL of 10mM HAuCl 4 Stirring the solution, adding 0.1mL of 100mM ascorbic acid solution to obtain a growth solution A, adding 0.08mL of 1.0mM chiral dipeptide (D-CF) solution into the growth solution A, adding 0.4mL of gold nano bipyramid solution D, and standing at 30 ℃ for 2 hours to obtain the chiral gold nano material D-GBPs with sea cucumber-like morphology.
Effect evaluation 1
Antibacterial tests were performed on PBS, PEG-Au NBP, examples 1,2 and 3, 100. Mu.L of bacterial suspension (2X 10 4 Staphylococcus epidermidis in (CFU)/mL (TSB) and 100. Mu.L of 0.01M PBS, PEG-Au NBPs, DL-GBPs, D-GBPs and L-GBPs were added to wells of a 96-well plate, respectively. The mixture was vortexed for 3min, then placed in an incubator for another 3h, and then irradiated with 808nm laser for 5min (0.8W/cm) 2 ). After irradiation, the mixture was incubated at 37℃for a further 12h. Finally, the value of the optical density was measured at 600nm using an enzyme-labeled instrument. The results are shown in FIG. 6, with bacterial suspensions cultured on non-irradiated samples as controls.
In a standard plate count assay, bacterial suspensions were serially diluted with 0.01M sterile PBS and 100. Mu.L of each diluted sample was plated onto a trypsin soybean agar plate. After incubation at 37℃for 12 hours, colonies formed on the surface of the plate were counted to evaluate the bacterial concentration. The results are shown in FIG. 7.
Effect evaluation 2
LIVE/DEAD staining assays of bacteria were performed on PBS, PEG-Au NBP and examples 1,2,3, and treated bacteria were stained with LIVE/DEAD BacLight bacterial viability kit and observed by Axio ver.a 1 fluorescence microscopy imaging system. The results are shown in FIG. 8.
Effect evaluation 3
SEM images were taken to observe the morphology of PBS, PEG-AuNBP, examples 1,2,3, both with and without radiation treatment.
The different treated staphylococcus epidermidis solutions were dropped onto a silicon wafer, then fixed with 2% glutaraldehyde at room temperature for 3h, then dehydrated with a series of gradient ethanol solutions (50%, 70%, 90%, 95% and 100%) for 10min each.
After drying the wafer under nitrogen flow, an ultra-thin gold coating was plated by sputtering and imaged at 3.0kV using a hitachi Su8010 instrument. The results are shown in FIG. 9.
As can be seen from a series of material performance characterization comparison, the sea cucumber-like chiral gold nano antibacterial material is successfully prepared. Tests of photo-thermal effect, bacterial survival performance and the like show that the chiral gold nanomaterial with the sea cucumber shape can sterilize through bacterial targeting and enhanced PTT effect, and the sterilization effect is obvious.
Therefore, the sea cucumber-like chiral gold nano antibacterial material prepared by the invention provides a promising nano tool for improving sepsis treatment effects, such as resisting fatal bacterial infection, regulating systemic inflammatory response, preventing multiple organ failure and the like.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations and modifications of the present invention will be apparent to those of ordinary skill in the art in light of the foregoing description. It is not necessary here nor is it exhaustive of all embodiments. And obvious variations or modifications thereof are contemplated as falling within the scope of the present invention.
Claims (8)
1. The chiral gold nano antibacterial material is characterized by being prepared by the following steps:
(1) To HAuCl 4 Adding citric acid solution into the solution, uniformly mixing, adding a reducing agent, and reacting to obtain gold seed solution;
(2) Performing heat treatment on the gold seed solution;
(3) Adding the gold seed solution after heat treatment into a water growth solution to obtain a gold nano bipyramid solution, wherein the water growth solution is a mixed solution of CTAB, silver nitrate, hydrochloric acid and ascorbic acid;
(4) Adding a chiral dipeptide aqueous solution and the gold nano bipyramid solution into a growth solution, and reacting to obtain the chiral gold nano antibacterial material, wherein the growth solution is prepared from CTAB and HAuCl 4 Adding ascorbic acid solution into the mixed solution of (a) to obtain;
the chiral dipeptide is L-CF, D-CF or DL-CF.
2. The chiral gold nano-antibacterial material according to claim 1, wherein in the step (1), the reducing agent is NaBH 4 And/or KBH 4 。
3. The chiral gold nano-antimicrobial material according to claim 1, characterized in that the concentration of the gold seed solution is 0.2-0.3mM.
4. The chiral gold nano-antibacterial material according to claim 1, wherein in the step (2), the heat treatment condition is stirring at 70-90 ℃ for 60-120min.
5. The chiral gold nano-antibacterial material according to claim 1, wherein in the step (3), the molar ratio of CTAB, silver nitrate, hydrochloric acid and ascorbic acid in the water growth solution is 1000:1-5:1-5:10-20.
6. The chiral gold nano-antibacterial material according to claim 1, wherein in the step (4), au in the gold nano-bipyramid solution 3+ 、CTAB、HAuCl 4 The molar ratio of the ascorbic acid to the chiral dipeptide is 1-25:5-100:1.5-4.5：7.5-12.5：0.04-0.12。
7. the chiral gold nano-antibacterial material according to claim 1, wherein in the step (4), the reaction condition is 25-35 ℃ for 1.5-2.5h.
8. The chiral gold nano-antibacterial material according to any one of claims 1-7, characterized in that the particle size of the chiral gold nano-antibacterial material is in the range of 80-150nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111633546.7A CN114309636B (en) | 2021-12-28 | 2021-12-28 | Chiral gold nano antibacterial material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111633546.7A CN114309636B (en) | 2021-12-28 | 2021-12-28 | Chiral gold nano antibacterial material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114309636A CN114309636A (en) | 2022-04-12 |
| CN114309636B true CN114309636B (en) | 2024-01-19 |
Family
ID=81014733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111633546.7A Active CN114309636B (en) | 2021-12-28 | 2021-12-28 | Chiral gold nano antibacterial material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114309636B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103240420A (en) * | 2013-05-24 | 2013-08-14 | 苏州大学 | Purification method for gold nano-particles with double-cone structures |
| CN105834451A (en) * | 2016-05-25 | 2016-08-10 | 东华大学 | Preparation method for gold nanoparticle bipyramids |
| CN110573280A (en) * | 2017-04-28 | 2019-12-13 | 乐金显示有限公司 | Metal nanostructure and method of making same |
| CN111112596A (en) * | 2018-11-01 | 2020-05-08 | 国家纳米科学中心 | Chiral noble metal nano-particles and preparation method and application thereof |
| CN111230136A (en) * | 2020-03-30 | 2020-06-05 | 江南大学 | Synthesis method of asymmetric chiral gold rod @ copper @ gold nanorod |
| CN111494618A (en) * | 2020-04-23 | 2020-08-07 | 江南大学 | Preparation method and application of chiral nano material adjuvant |
| KR20210041504A (en) * | 2019-10-04 | 2021-04-15 | 서울대학교산학협력단 | Method of fabricating 3-dimensional chiral metal nanostructure and 3-dimensional chiral metal nanostructure fabricated therefrom |
| CN112828283A (en) * | 2020-12-31 | 2021-05-25 | 纳米籽有限公司 | High-purity gold nanoparticles, selectively-coated gold nanoparticles and preparation method thereof |
| CN112889840A (en) * | 2021-01-15 | 2021-06-04 | 南京农业大学 | Chiral cysteine nano self-assembly antibacterial material and preparation method and application thereof |
-
2021
- 2021-12-28 CN CN202111633546.7A patent/CN114309636B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103240420A (en) * | 2013-05-24 | 2013-08-14 | 苏州大学 | Purification method for gold nano-particles with double-cone structures |
| CN105834451A (en) * | 2016-05-25 | 2016-08-10 | 东华大学 | Preparation method for gold nanoparticle bipyramids |
| CN110573280A (en) * | 2017-04-28 | 2019-12-13 | 乐金显示有限公司 | Metal nanostructure and method of making same |
| CN111112596A (en) * | 2018-11-01 | 2020-05-08 | 国家纳米科学中心 | Chiral noble metal nano-particles and preparation method and application thereof |
| KR20210041504A (en) * | 2019-10-04 | 2021-04-15 | 서울대학교산학협력단 | Method of fabricating 3-dimensional chiral metal nanostructure and 3-dimensional chiral metal nanostructure fabricated therefrom |
| CN111230136A (en) * | 2020-03-30 | 2020-06-05 | 江南大学 | Synthesis method of asymmetric chiral gold rod @ copper @ gold nanorod |
| CN111494618A (en) * | 2020-04-23 | 2020-08-07 | 江南大学 | Preparation method and application of chiral nano material adjuvant |
| CN112828283A (en) * | 2020-12-31 | 2021-05-25 | 纳米籽有限公司 | High-purity gold nanoparticles, selectively-coated gold nanoparticles and preparation method thereof |
| CN112889840A (en) * | 2021-01-15 | 2021-06-04 | 南京农业大学 | Chiral cysteine nano self-assembly antibacterial material and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 一种通用的合成多刺状的银@金和银@金@银纳米结构的方法用于提高表面增强拉曼的活性;许富刚;谢施;任春锦;冯亚楠;曹仁涛;;吉林师范大学学报(自然科学版);第38卷(第01期);第19-26页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114309636A (en) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Soliman et al. | Green approach to overcome the resistance pattern of Candida spp. using biosynthesized silver nanoparticles fabricated by Penicillium chrysogenum F9 | |
| Li et al. | Noninvasive rapid bacteria-killing and acceleration of wound healing through photothermal/photodynamic/copper ion synergistic action of a hybrid hydrogel | |
| Zhang et al. | Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles | |
| Miao et al. | Papain-templated Cu nanoclusters: assaying and exhibiting dramatic antibacterial activity cooperating with H 2 O 2 | |
| Vertelov et al. | A versatile synthesis of highly bactericidal Myramistin® stabilized silver nanoparticles | |
| Kahzad et al. | Green synthesis of CuFe2O4@ Ag nanocomposite using the Chlorella vulgaris and evaluation of its effect on the expression of norA efflux pump gene among Staphylococcus aureus strains | |
| Ranganath et al. | Screening of Lactobacillus spp, for mediating the biosynthesis of silver nanoparticles from silver nitrate | |
| Wang et al. | Construction of perfluorohexane/IR780@ liposome coating on Ti for rapid bacteria killing under permeable near infrared light | |
| CN114306382B (en) | Copper-based nanoenzyme as well as preparation method and application thereof | |
| Park et al. | Advanced carbon dots via plasma-induced surface functionalization for fluorescent and bio-medical applications | |
| CN113016823B (en) | Preparation method of photo-thermal antibacterial near-infrared bimetallic nanoparticles | |
| Mosselhy et al. | Silver nanoparticles: in vivo toxicity in zebrafish embryos and a comparison to silver nitrate | |
| Zhang et al. | Fabrication of mesoporous La 3 Ga 5 GeO 14: Cr 3+, Zn 2+ persistent luminescence nanocarriers with super-long afterglow for bioimaging-guided in vivo drug delivery to the gut | |
| Liu et al. | Fabrication of AgBr nanomaterials as excellent antibacterial agents | |
| Yan et al. | Atomic-engineered gold@ silvergold alloy nanoflowers for in vivo inhibition of bacteria | |
| Deng et al. | Facile synthesis of long-term stable silver nanoparticles by kaempferol and their enhanced antibacterial activity against Escherichia coli and Staphylococcus aureus | |
| Ediz et al. | Green synthesis of silver nanoparticles from Phaseolus vulgaris L. extracts and investigation of their antifungal activities | |
| Chakraborty et al. | Silver nanoparticle synthesis and their potency against multidrug-resistant bacteria: a green approach from tissue-cultured Coleus forskohlii | |
| CN114309636B (en) | Chiral gold nano antibacterial material and preparation method thereof | |
| Alheshibri et al. | Synthesis of highly stable Ag/Ta2O5 nanocomposite by pulsed laser ablation as an effectual antibacterial agent | |
| CN114734032A (en) | Method for preparing nano-silver based on kapok extract | |
| Zhou et al. | Potent intrinsic bactericidal activity of novel copper telluride nano-grape clusters with facile preparation | |
| Faiq et al. | Inhibitory effects of biosynthesized copper nanoparticles on biofilm formation of Proteus mirabilis | |
| CN115025044B (en) | Antibacterial poly-tannic acid nanoparticle PTA NPs and preparation method thereof | |
| Sánchez-Sanhueza et al. | Synthesis of copper nanowires and their antimicrobial activity on strains isolated persistent endodontic infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |